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ABSTRACT
Objective: To investigate the effects of topiramate (TPM), zonisamide (ZNS), and levetiracetam
(LEV) on cognitive network activations in patients with focal epilepsy using an fMRI language task.
Methods: In a retrospective, cross-sectional study, we identified patients from our clinical data-
base of verbal fluency fMRI studies who were treated with either TPM (n 5 32) or ZNS (n 5
51). We matched 62 patients for clinical measures who took LEV but not TPM or ZNS. We
entered antiepileptic comedications as nuisance variables and compared out-of-scanner psycho-
metric measures for verbal fluency and working memory between groups.
Results: Out-of-scanner psychometric data showed overall poorer performance for TPM com-
pared to ZNS and LEV and poorer working memory performance in ZNS-treated patients com-
pared to LEV-treated patients. We found common fMRI effects in patients taking ZNS and
TPM, with decreased activations in cognitive frontal and parietal lobe networks compared to
those taking LEV. Impaired deactivation was seen only with TPM.
Conclusions: Our findings suggest that TPM and ZNS are associated with similar dysfunctions of
frontal and parietal cognitive networks, which are associated with impaired performance. TPM is
also associated with impaired attenuation of language-associated deactivation. These studies
imply medication-specific effects on the functional neuroanatomy of language and working mem-
ory networks.
Classification of evidence: This study provides Class III evidence that in patients with focal epi-
lepsy, TPM and ZNS compared to LEV lead to disruption of language and working memory
networks. Neurology® 2017;88:1–7
GLOSSARY
AED 5 antiepileptic drug; DMN 5 default mode network; IFG 5 inferior frontal gyri; LEV 5 levetiracetam; MFG 5 middle
frontal gyri; TPM 5 topiramate; ZNS 5 zonisamide.
Among newer antiepileptic drugs (AEDs), highest rates of cognitive impairment have been re-
ported for topiramate (TPM; Topamax; Janssen-Cilag, Neuss, Germany) and zonisamide (ZNS;
Zonegran; EISAI, Tokyo, Japan), leading to early treatment discontinuation.1 For TPM, cog-
nitive dysfunction is specifically characterized by impairment of expressive language and work-
ing memory. ZNS treatment leads to similar, less pronounced impairment.2,3 The mechanisms
of these specific impairment patterns are poorly understood. Five cognitive fMRI studies used
language tasks in 2 healthy participants, 5 to 16 patients with epilepsy, and 10 patients with
migraine after a single dose or on steady-state TPM treatment. Taken together, the following
patterns of dysfunctional activation emerge: decreased activation in task-positive regions, i.e.,
dominant inferior and middle frontal gyri (IFG and MFG),4–6 and failure to deactivate task-
negative regions, including the default mode network (DMN).5,7,8
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Only one study investigated potential
pathomechanisms of cognitive impairment
due to ZNS, describing decreased current-
source density of high beta frequency in regions
relevant to language and working memory
during a verbal fluency task.9 All of the above
studies are hampered by small sample sizes.
We therefore aimed to investigate in a larger
group of patients than previous studies how
TPM and ZNS alter fMRI activation patterns
to identify patients at risk of developing cognitive
side effects. On the basis of previously observed
effects of levetiracetam (LEV; Keppra; UCB,
Brussels, Belgium) leading to normalization of
cognitive network activation in focal epilepsy,10
we selected patients on LEV as a comparison
group to control for disease-related effects.
METHODS Participants. In this cross-sectional study, we
chose patients retrospectively from a clinical database of patients
with drug-refractory epilepsy who had undergone clinical
language fMRI scans at the UCL Chalfont Centre for Epilepsy
(UK) between March 2010 and October 2015 as part of their
presurgical evaluation. All patients were adults and seen at the
adult epilepsy clinics of the National Hospital for Neurology and
Neurosurgery and Chalfont Centre for Epilepsy. We included
patients who were taking 1 of the following 3 AEDs: TPM,
ZNS, or LEV, either alone or with other AEDs as comedications.
As requirements for patients’ testability with the language
fMRI paradigm, all patients had to be literate, proficient in the
English language, and cognitively able to understand the simple
task instructions (see paradigm description below). Our standard
clinical language fMRI paradigm is conducted covertly; hence, we
could not control for task compliance. For this reason, we
excluded all patients without activations of language-relevant
regions (IFG and MFG) from the analysis. We also excluded
patients with data acquired postoperatively and those with large
lesions or tumors (.2 cm) to avoid problems with imaging nor-
malization and further statistical analysis. Seventy-eight patients
on LEV, 51 on ZNS, and 32 on TPM were eligible. To create
more balanced group sizes and to ensure that the TPM and ZNS
groups were comparable in demographics and clinical character-
istics to the LEV group, we used propensity score matching. We
started with the ZNS and TPM groups and in each group looked
for propensity-matched LEV patients for the variables of age at
scan, age at disease onset, sex, language laterality index, total
number of medications, and lesion laterality using propensity
scores in SPSS version 21.0. We included 51 patients on ZNS,
32 on TPM, and 62 on LEV in the final analysis. All patients had
refractory focal epilepsy, and ictal EEG data were available in
86% of cases. Table 1 and table e-1 at Neurology.org provide
further clinical details.
Primary research question and classification of level of
evidence. The primary research goal was to assess the effect of
TPM and ZNS on language task fMRI activation and deactiva-
tion in patients with focal epilepsy (level of evidence: Class III).
MRI data acquisition and fMRI paradigm. Gradient echo-
planar images were acquired for blood oxygen level–dependent
contrast on a 3T General Electric Excite HDx scanner (General
Electric, Milwaukee, WI).
Each volume comprised 50 contiguous oblique axial slices, pro-
viding full brain coverage, with 2.5-mm slice thickness, 64 3 64
matrix, 24-cm field of view, 3.75 3 3.75-mm in-plane resolution,
25-millisecond echo time, and 2.5-second repetition time.
Patients performed a covert verbal fluency task lasting for
5.5 minutes. During the paradigm, 30-second blocks of task alter-
nated with 30-second blocks of cross-hair fixation as a control con-
dition. Patients were instructed to covertly generate words starting
with a visually presented letter (A, D, E, S, W).
fMRI data analysis. fMRI analysis was performed with Statis-
tical Parametric Mapping-8, version 4290 (http://www.fil.ion.
ucl.ac.uk/spm/). Preprocessing included realignment, spatial
normalization to a template in Montreal Neurological Institute
Table 1 Clinical measures
On LEV (n 5 62) On ZNS (n 5 51) On TPM (n 5 32) df p Value
Age, median (IQR), y 34 (26–42) 35 (29–42) 35 (28–47) 2 0.804
Male sex, n 27 28 14 2 0.43
Handedness (right/left/ambidextrous), n 55/5/1 42/7/1 25/6/1 4 0.631
Age at onset, median (IQR), y 14 (7–21) 13 (6–19) 11 (6–18) 2 0.610
Duration, median (IQR), y 18 (12–26) 22 (13–31) 23 (10–30) 2 0.362
Ictal EEG available, n 52 45 28 2 0.64
Lesion, one/bilateral/left/right, n 25/2/19/16 26/0/15/10 15/3/6/8 6 0.284
Dose, median (IQR), mg 2,000 (1,250–3,000) 225 (150–400) 312.5 (200–500) 2 N/A
AEDs, median (IQR), n 2 (2–3) 2 (2–3) 3 (2–3) 2 0.245
Patients on monotherapy vs polytherapy 5/57 4/47 4/28 2 0.730
Laterality index, median (IQR) 0.75 (0.53–0.85) 0.77 (0.55–0.92) 0.72 (0.23–0.84) 2 0.391
Scanned on upgraded scanner, n 26 27 8 2 0.041
Abbreviations: AED 5 antiepileptic drug; IQR 5 interquartile range between pair of quartiles; LEV 5 levetiracetam; TPM 5
topiramate; ZNS 5 zonisamide.
Pearson x2 was used for dichotomous variables, and Kruskal-Wallis test was used for all other variables (p , 0.05).
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space, resampling to isotropic 3 3 3 3 3 voxels, and smoothing
with a gaussian kernel of 8-mm full-width at half-maximum.
We performed the statistical fMRI analyses at the first level,
i.e., single subject, and then at the group level. At the first level,
the task was modeled by convolving the vector of block onsets
with a canonical hemodynamic response function to create
regressors of interest. Movement parameters were included as
confounds. Contrast images for each participant were created
for task-relevant activation and deactivation.
At the second level, we first explored activation and deactiva-
tion maps during the verbal fluency task in each patient group using
one-sample t tests (figure 1, figure e-1). For group comparisons,
second-level analysis was conducted by entering the activation con-
trast of each patient into a full factorial design with group (LEV,
ZNS, TPM) as a factor. All other AEDs were entered as regressors
of no interest. Because the scanner was upgraded in 2013, this was
entered as an additional covariate of no interest (scanned on up-
graded scanner yes/no). An exploratory statistical threshold was set
at p , 0.005 uncorrected with a 20-voxel minimum cluster size
extent threshold.11 To be able to disentangle whether group
differences were related to activation or deactivation, we masked
the results with a binarized average task activation map of the
controls and subsequently with the binarized deactivation map to
include the contrast-relevant brain areas.
Interpretation of the results at the first level and group level
was not blinded because resultant maps represent t maps at a pre-
defined statistical threshold. We anatomically objectified peak
activations from group comparisons with coordinates in Montreal
Neurological Institute space.
Laterality index. To control for differences in language lateral-
ity, we matched the groups for laterality indexes. These were cal-
culated with the bootstrap method in the Statistical Parametric
Mapping-8 LI toolbox12 for the verbal fluency activation
contrast for each participant in the IFG and MFG.
Cognitive measures. In those patients who had standard clinical
psychometric testing at the time of the scan, we carried out sub-
group analyses of performances. We included tests measuring cog-
nitive domains reported to be affected by TPM and ZNS: letter and
category fluency, the Wechsler Adult Intelligence Scale Digit Span
Figure 1 Group activation and deactivation maps during the verbal fluency task
One-sample t tests of fMRI activation and deactivation maps for the 3 different patient groups on levetiracetam, zonisa-
mide, and topiramate are demonstrated on a surface-rendered brain template. Task-relevant regions (red) include bilateral
inferior and middle frontal gyrus (left . right), bilateral supplementary motor area, and the left dorsolateral parietal region.
Areas of task-related deactivations (blue) include the bilateral precuneus, posterior cingulate, angular gyrus, and medial
prefrontal and lateral temporal cortex. p , 0.005, 20-voxel threshold extent.
Table 2 Cognitive performance
LEV ZNS TPM df p Value
WAIS Digit Span, median (IQR) 9 (7.5–11) (n 5 42) 7 (6–9) (n 5 36) 5 (4.75–7) (n 5 20) 2 ,0.001
Letter fluency, median (IQR) 14.5 (10.25–17.75) (n 5 38) 12 (8–15) (n 5 35) 10 (8–11.5) (n 5 20) 2 0.003
Categorical fluency, median (IQR) 18.5 (15–25.75) (n 5 39) 17 (15–22) (n 5 35) 12 (11–16) (n 5 20) 2 ,0.001
Naming (GNT), median (IQR) 17 (13.45–21.25) (n 5 34) 17 (14–20) (n 5 28) 14 (10.5–17) (n 5 15) 2 0.391
Abbreviations: GNT 5 Grades Naming Test; IQR 5 interquartile range between pair of quartiles; LEV 5 levetiracetam; TPM 5 topiramate; WAIS 5Wechsler
Adult Intelligence Scale; ZNS 5 zonisamide.
Kruskal-Wallis test, p , 0.05.
Scaled scores are presented for digit span; raw scores are presented for all other cognitive measures.
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measure of short term and working memory, and the GradedNam-
ing Test measure of expressive language function.13
Statistical analysis of clinical and behavioral data was con-
ducted with SPSS version 21.0 (IBM, Armonk, NY). We applied
x2 tests to categorical data and the Kruskal-Wallis or Mann-
Whitney U test to all other measures. The statistical significant
threshold was set at p , 0.05.
Standard protocol approvals, registrations, and patient
consents. This study was approved by the Joint Ethics Committee
of the National Hospital for Neurology and Neurosurgery and
University College London Institute of Neurology. The Research
Ethics Committee classified this work as evaluation of clinical
services, i.e., routine language fMRI; therefore, individual consent
from patients was not needed.
RESULTS Cognitive performance. There were signifi-
cant group differences in cognitive test performance with
the exception of the Graded Naming Test (table 2).
Post hoc group comparisons revealed that for the
digit span task, patients on LEV performed better than
both those on ZNS and TPM (LEV vs ZNS: U 5
451000, p5 0.002; LEV vs TPM: U5 120000, p,
0.001, Mann-Whitney U test), and those on ZNS
performed better than patients on TPM (LEV vs
ZNS:U5 205000, p5 0.007). TPM-treated patients
performed less well than both LEV- and ZNS-treated
patients on both fluency measures (LEV vs TPM: let-
ter fluency U 5 177000, p 5 0.001, category fluency
U5 149500, p, 0.001; ZNS vs TPM: letter fluency
U 5 237000, p 5 0.047; category fluency U 5
145500, p , 0.001). There was no statistical
difference between LEV- and ZNS-treated patients
(letter fluency U 5 505500; p 5 0.077; category
fluency U 5 604500, p 5 0.397).
fMRI results. As demonstrated by one-sample t tests of
task-relevant activations and deactivations, each AED
group activated frontal language areas, including the
IFG, MFG, bilateral supplementary motor areas, and
left lateral parietal region, and deactivated areas of the
DMN, i.e., bilateral precuneus, posterior cingulate,
angular gyrus, and medial prefrontal and lateral
temporal cortices (figure 1, figure e-1).
Comparison of TPM, ZNS, and LEV groups. Patients
receiving TPM showed reduced activation in the left
MFG and left dorsal parietal region compared to those
taking LEV (figure 2A, figure e-2). Similarly, those on
ZNS had reduced activation in the bilateral MFG and
IFG and the left dorsal parietal region compared to
patients on LEV (figure 2B, figure e-2). Compared
to LEV patients, TPM- but not ZNS-treated
patients showed less task-related deactivation in the
temporal regions and the rolandic opercula
bilaterally, as well as the right inferior parietal lobule
and supramarginal gyrus (figure 2C, figure e-2).
Comparing TPM- and ZNS-treated patients
directly revealed greater activation in the temporal
regions and rolandic opercula bilaterally and the insu-
lar cortex, inferior parietal lobule, supramarginal
gyrus, superior temporal gyrus, and rolandic opercu-
lum on the right in the TPM group (figure 2D, figure
e-2). Group differences on the right were due mainly
to impaired deactivation compared to LEV and ZNS
(masked inclusively for LEV and ZNS group deacti-
vation maps; shown in blue in figure 2D). Left-sided
changes were located within LEV group activation
maps and hence were due to greater task-relevant
activation in TPM (shown in red in figure 2D).
Figure 2 Group differences in fMRI activation
maps during the verbal fluency task
Significant group differences between patients on levetir-
acetam (LEV), topiramate (TPM), and zonisamide (ZNS)
are demonstrated. Patients on TPM and ZNS have less acti-
vation in frontal and parietal cognitive networks than pa-
tients on LEV. In patients on TPM, activation is reduced in
the left middle frontal gyrus (MFG) and left dorsal parietal
region (A). In patients on ZNS, activation is reduced in the
left MFG and bilateral inferior frontal gyrus (IFG), as well
as the left dorsal parietal region (B). In terms of task-rele-
vant deactivation networks, bilateral lateral temporal re-
gions and rolandic opercula and the right inferior parietal
lobule and supramarginal gyrus are less deactivated (blue)
in patients on TPM compared to those on LEV (C). Com-
pared to ZNS, TPM shows increased activation in the IFG,
insular cortex, and rolandic operculum on the left and the
insular cortex, inferior parietal lobule, supramarginal gyrus,
superior temporal gyrus, and rolandic operculum on the
right. Differences in the left are due mainly to increased
activation of task-relevant regions as shown in red (inclu-
sively masked with LEV activation maps); on the right, acti-
vated regions lie mainly within task-negative areas, i.e., are
due to impaired deactivation as shown in blue (inclusively
masked with LEV and ZNS deactivation maps) (D). p ,
0.005, 20-voxel threshold extent.
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There were no regions of greater activation in
ZNS-treated patients compared to those on TPM.
Table 3 gives a more detailed anatomic description of
resultant regions from the individual group comparisons.
DISCUSSION In this study, we demonstrate language
paradigm–specific fMRI effects with a decrease in
frontal lobe and parietal lobe activations common to
ZNS and TPM and impaired deactivation in task-
negative networks seen only for TPM.
Our results concur with findings from previous
studies on TPM reporting decreased task-relevant fron-
tal activation or impaired deactivation of task-negative
networks4,5,7,8 and demonstrate both mechanisms in
a larger group of patients. We found that ZNS is
associated with similar dysfunctional networks of task
activation but that impaired deactivation appears to be
specific to TPM, as shown in comparison to both
LEV- and ZNS-treated patients.
The verbal fluency fMRI task usually leads to acti-
vation of frontal lobe areas, including most consis-
tently the dominant IFG, MFG, anterior cingulate,
and precentral cortices, as well as the insular, superior
temporal, and parietal cortices and the cerebellum
(contralateral to frontal activation).14–16 Dorsolateral
frontal and parietal cortices activated by the verbal
fluency task are also implicated in functional net-
works of working memory and attention.17,18 Given
the low-demand control condition in the verbal flu-
ency task used in this study, activation of cognitive
networks supporting general task performance, i.e.,
the working memory and sustained attention system,
becomes apparent with increasing task demand, in
addition to activation of language-specific frontal net-
works.19 Hence, decreased activation in both regions
relevant for expressive language function (i.e., IFG,
MFG) and general cognitive task performance, i.e.,
the parietal cortex for sustained attention and the
frontoparietal working memory network, suggests
suppression of several higher-level cognitive domains
by TPM and ZNS.
In TPM-treated patients, fMRI changes involved
both activation and deactivation networks. Task-
related deactivation refers to a decrease in blood oxygen
level–dependent signal during demanding motor or
cognitive tasks compared to less demanding states such
as resting. Deactivation likely occurs because neural
processes during these less demanding states are in-
terrupted by engagement with the task and a shift from
internal to external information processing. Successful
task execution has been associated with effective
deactivation of task-negative areas.20,21 It has recently
been demonstrated that the DMN is segregated into
subspecialized nodes and, more relevant to our study,
that there is functional heterogeneity across DMN no-
des with respect to different language tasks.21,22 In
addition, areas involved in semantic and language pro-
cessing show a large overlap with regions of the DMN
(i.e., angular gyrus, medial prefrontal cortex, IFG, pos-
terior cingulate, ventral temporal lobe).19 Deactivation
in those overlapping regions can be modulated by both
task content, i.e., high semantic demands reducing
deactivation, and increased task demands or difficulty
leading to increased deactivation.19,21 In our study,
patients on TPM failed to deactivate task-relevant
DMN nodes compared to patients taking ZNS or
LEV, associated with more cognitive impairment than
those on ZNS, and these include areas implicated in
language processing (i.e., right inferior parietal lobule,
supramarginal gyrus). In addition, direct comparison
Table 3 Anatomic description and peak activations of resultant areas from
group comparisons
Region MNI coordinates (x, y, z) z Score p Value
Patients on LEV > patients on TPM
Left dorsal parietal 248, 243, 43 3.94 ,0.001
Left middle frontal gyrus 239, 5, 34 3.90 ,0.001
Left inferior temporal gyrus 254, 240, 220 3.55 ,0.001
Left superior temporal gyrus 245, 14, 211 3.38 ,0.001
Left supplementary motor area 29, 23, 49 2.90 0.002
Patients on LEV > patients on ZNS
Left inferior frontal gyrus 242, 5, 34 4.07 ,0.001
Left dorsal parietal 227, 264, 40 3.93 ,0.001
Left inferior temporal gyrus 248, 246, 211 3.35 ,0.001
Left middle frontal gyrus 245, 32, 28 3.68 ,0.001
Right inferior frontal gyrus 48, 32, 22 3.51 ,0.001
Right middle frontal gyrus 36, 50, 7 3.20 0.001
Patients on TPM > patients on LEV
Left rolandic operculum 236, 231, 19 3.48 ,0.001
Left temporal lobe 242, 225, 211 3.14 0.001
Left superior temporal gyrus 254, 27, 4 3.17 0.001
Right rolandic operculum/inferior parietal
lobule/supramarginal gyrus
45, 225, 22 3.88 ,0.001
Right temporal lobe 42, 219, 28 3.36 ,0.001
Right superior temporal gyrus 51, 213, 7 3.16 0.001
Right precuneus 9, 249, 55 2.96 0.002
Patients on TPM > patients on ZNS
Left inferior frontal gyrus 248, 21, 19 4.07 ,0.001
Left insula 230, 24, 13 3.00 0.001
Left anterior cingulate gyrus 218, 35, 16 3.35 ,0.001
Right rolandic operculum/inferior parietal
lobule/supramarginal gyrus
54, 213, 22 3.98 ,0.001
Right insula/right rolandic operculum/right
superior temporal gyrus
48, 27, 10 3.70 ,0.001
Right medial frontal gyrus 12, 56, 16 3.31 ,0.001
Abbreviations: LEV 5 levetiracetam, MNI 5 Montreal Neurological Institute, TPM 5 top-
iramate, ZNS 5 zonisamide.
Coordinates are given in MNI space.
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to ZNS reveals that TPM leads to failed deactivation of
language-task relevant DMN nodes on the right but
increased activation of language-relevant task-positive
regions on the left (figure 2D, figure e-2). The latter, as
demonstrated by psychometric out-of-scanner data, is
ineffective.
A particular strength of our study is the big sample
size. As a limitation, the statistical threshold used for
the second-level analysis, i.e., p, 0.005 uncorrected,
20-voxel threshold extent, enables an exploratory
view of the differences between AED treatment
groups, although peak activations within implicated
regions almost all survive p , 0.001 uncorrected
(table 3). Findings need to be confirmed in a follow-up
study with larger patient groups. Interpretation of
findings may be limited in that patients on TPM
and ZNS were compared only to those on LEV.
However, the reported effects of LEV10 have been
toward restoration of normal activation patterns,
justifying our choice as a patient control group.
Detrimental effects of TPM were demonstrated even
when compared to ZNS only. In addition, LEV is
comparable to ZNS and TPM in its clinical application
of a commonly used broad-spectrum AED.
There is a potential case selection bias because our
study included only patients who continued treat-
ment on TPM and ZNS and hence may have benefit-
ted more and experienced fewer side effects than
those who stopped these medications. A further
potential confounder is the reason why a particular
medication was chosen for a patient. All 3 drugs are
broad-spectrum AEDs with an uncomplicated inter-
action profile with other AEDs and have been estab-
lished for several years in the treatment of epilepsy in
general and in polytherapy in refractory epilepsy.23–25
However, we cannot control for treatment preferen-
ces in certain patients, e.g., choosing TPM in those
who also have migraines. More than 10 consultants
are involved in epilepsy treatment at our center, sup-
porting that the AED profile of our groups is not
driven by the personal choices of a few individuals;
however, AED choices in our epilepsy center may
differ from those in others.
The majority of patients were on comedication,
which may have contributed to poor cognitive perfor-
mance and contributed noise to the data. It has been
shown that every additional AED leads to further cog-
nitive impairment.26 AED plasma concentrations
were not known at the time of scanning. Although
we cannot fully control for effect of comedication, we
matched groups for the median number of AEDs,
and individual comedication AEDs were included as
a regressor of no interest in the fMRI analysis model,
which is a standard methodology in fMRI analysis.
Although future studies in patients on monotherapy
are necessary to fully control for comedication effects,
we stress that considering which AED to choose next
in a treatment-refractory patient already on polyther-
apy is a common clinical dilemma, and findings here
may eventually help the clinician’s choice.
Out-of-scanner psychometric data were available
in only a subset of patients.
Because of the retrospective study design, the effect
of seizures on our findings could not be quantified in
terms of frequency, severity, or proximity to scan time.
All patients had refractory epilepsy; we therefore
assume similar effects of seizures in all groups.
Although all patients had focal epilepsy, different
epilepsy syndromes were included (table e-1). Our
study characterizes TPM/ZNS-related disruption of
language and working memory networks in a relatively
large group of presurgical candidates of a big tertiary
epilepsy referral center. Although our findings are
not fully generalizable because medical treatment strat-
egies and drug choices may differ across epilepsy cen-
ters and countries, observed fMRI results in this
study still provide valuable information for interpreting
clinical language fMRI scans in a variety of patients.
With respect to clinical applications, task-, region-,
and AED-specific effects of TPM and ZNS may help
to identify patients at risk of developing AED-related
side effects at an early stage of treatment. So far, group
studies have shown high sensitivity of pharmaco-
fMRI, detecting negative drug effects on neuronal
networks even after a single-dose application.7 Pro-
spective longitudinal studies, enabling fMRI and psy-
chometric data collection before and when TPM and
ZNS are initiated (ideally with plasma levels), will
help to elucidate why certain patients develop cogni-
tive side effects on a specific drug and others do not.
To date, pharmaco-fMRI could not be implemented
as a standard tool at single-patient level because of the
costs and because the limits of normal and abnormal
activations at single-patient level so far cannot be
quantified.
Identifying language lateralization with fMRI is
crucial for risk assessment during planning for epilepsy
surgery.27 It would thus be important to establish
whether fMRI changes due to TPM and ZNS can lead
to mislateralization of language. In this study, because
groups were matched for laterality index to increase the
yield by including patients regardless of language lat-
eralization, we cannot comment on a potential effect of
TPM and ZNS on laterality indexes, and this will be
more appropriately answered in longitudinal studies
before and after treatment initiation.
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